UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039787
Receipt number R000045359
Scientific Title Study of Association between Pulmonary artery pressure and Cardiac acoustic biomarker
Date of disclosure of the study information 2020/03/31
Last modified on 2022/12/26 16:04:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of Association between Pulmonary artery pressure and Cardiac acoustic biomarker

Acronym

Study of Association between Pulmonary artery pressure and Cardiac acoustic biomarker
- SAP-C -

Scientific Title

Study of Association between Pulmonary artery pressure and Cardiac acoustic biomarker

Scientific Title:Acronym

Study of Association between Pulmonary artery pressure and Cardiac acoustic biomarker
- SAP-C -

Region

Japan


Condition

Condition

Heart failure patients who are due to undergo right heart catheterization

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study examines the relationship between CAB which captures S2 characteristics, and PAP changes, explores new possibilities of PAP monitoring using CAB, and investigates the relationship with the heart failure state by concurrently analyzing the conventional EMAT and S3 characteristics. Heart sounds and ECG are measured concurrently during right heart catheterization to accurately measure CAB responsiveness to changes in PAP and other hemodynamic indicators related to heart failure.

Basic objectives2

Others

Basic objectives -Others

1. CAB values relating to S2 characteristics measured at the 3L position, and PAP values (peak value during exercise) measured at each of the following points in provocative testing during right heart catheterization: baseline (at rest), exercise (provocation), and cool-down (at rest).
2. CAB values measured at the Apex and 3L positions, and PAP values and hemodynamic indicators other than PAP (PCWP, CO, etc.) measured at each of the following points in provocative testing during right heart catheterization: baseline (at rest), exercise (provocation), cool-down (at rest).

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

1. CAB values relating to S2 characteristics measured at the 3L position, and PAP values (peak value during exercise) measured at each of the following points in provocative testing during right heart catheterization: baseline (at rest), exercise (provocation), cool-down (at rest).
2. CAB values measured at the Apex and 3L positions, and PAP values and hemodynamic indicators other than PAP (PCWP, CO, etc.) measured at each of the following points in provocative testing during right heart catheterization: baseline (at rest), exercise (provocation), cool-down (at rest).

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients who are aged 20 years or older at the time of acquisition of informed consent
2) Heart failure patients who are due to undergo right heart catheterization
3) Patients who have given written consent to participate in this study

Key exclusion criteria

1) Patients with severe aortic stenosis or degenerative mitral insufficiency
2) Patients after mechanical valve replacement
3) Patients using assisted circulation apparatus such as LVAD or IABP
4) Patients with complications of malignant tumors
5) Patients who are pregnant, may be pregnant, or are nursing
6) Other patients deemed ineligible at the discretion of the principal investigator or sub-investigator

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Koichi
Middle name
Last name Node

Organization

Saga University

Division name

Department of Cardiovascular Medicine

Zip code

849-8501

Address

5-1-1 Nabeshima, Saga

TEL

0952-34-2364

Email

cardiostudy@ml.cc.saga-u.ac.jp


Public contact

Name of contact person

1st name Norihiko
Middle name
Last name Kotooka

Organization

Saga University

Division name

Department of Cardiovascular Medicine

Zip code

849-8501

Address

5-1-1 Nabeshima, Saga

TEL

0952-34-2364

Homepage URL


Email

cardiostudy@ml.cc.saga-u.ac.jp


Sponsor or person

Institute

Department of Cardiovascular Medicine, Saga University

Institute

Department

Personal name



Funding Source

Organization

Asahi Kasei Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Asahi Kasei Corporation

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Center,Saga University Hospital

Address

5-1-1 Nabeshima, Saga

Tel

0952-34-3400

Email

kenkyu-shinsei@ml.cc.saga-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

佐賀大学


Other administrative information

Date of disclosure of the study information

2020 Year 03 Month 31 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

50

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 12 Month 26 Day

Date of IRB

2020 Year 02 Month 03 Day

Anticipated trial start date

2020 Year 04 Month 01 Day

Last follow-up date

2021 Year 11 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective observational study


Management information

Registered date

2020 Year 03 Month 12 Day

Last modified on

2022 Year 12 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045359


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name